Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference

PR Newswire June 19, 2014

Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs of $200 to $240 for Two Days of Post-Surgical Pain Management

PR Newswire June 3, 2014

AcelRx Pharmaceuticals Announces The Departure Of David Chung

PR Newswire June 2, 2014

AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

PR Newswire May 29, 2014

AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

PR Newswire May 19, 2014

AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results

PR Newswire May 8, 2014

AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014

PR Newswire May 2, 2014

AcelRx Pharmaceuticals Announces Zalviso(TM) and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting

PR Newswire May 1, 2014

AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference

PR Newswire April 4, 2014

Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies

Business Wire April 1, 2014

AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer

PR Newswire March 25, 2014

AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference

PR Newswire March 7, 2014

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

PR Newswire March 3, 2014

AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014

PR Newswire February 24, 2014

AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events

PR Newswire February 5, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on ACRX, IPXL, MYL and TEVA

Accesswire January 8, 2014

Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors

Business Wire January 6, 2014

AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital

PR Newswire December 19, 2013

Annual Changes to the NASDAQ Biotechnology Index

Globe Newswire December 16, 2013

AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)

PR Newswire December 16, 2013